Previously the indication was only for adult use; The medicine is part of the remedies popularly known as weight loss pens.
The National Health Surveillance Agency (Anvisa) approved this Wednesday (22) the use of the drug Mounjaro to treat type 2 diabetes em children from 10 years old. Until then, the indication was only for adult use.
In a note, Anvisa informed that the other indications for the medicine remain for adult use. “The only change was the expansion of the target population for diabetes treatment, which was only for adult use and is now for pediatric use.”
Mounjaro is one of several medications in the class of GLP 1 receptor agonists, popularly known as slimming pens.
Manipulation
Next week, Anvisa’s board of directors will discuss a proposal for normative instructions on procedures and technical requirements that will deal with the handling of weight-loss pens.
The new standard will be part of a set of strategies that are part of the action plan announced on the 6th, consisting of regulatory measures and of oversight related to this type of medication.
Working groups
Last week, the agency published ordinances that create two working groups to support the authority’s work in health control and guarantee the safety of patients who use weight-loss pens.
The first group, formalized by Ordinance 488/2026, will be formed by representatives of the Federal Pharmacy Council (CFF), do Federal Council of Medicine (CFM) e do Federal Council of Dentistry (CFO).
Ordinance 489/2026 establishes the second group, which will to accompany e to assess the implementation of an action plan proposed by Anvisa and support the decision-making of the collegiate board by proposing improvement measures.
*With information from Agência Brasil
